Research & Development

Infant Bacterial Therapeutics' most advanced clinical program is the IBP-9414 project developing a preventive treatment against necrotizing enterocolitis (NEC)   ☛ The phase II safety and tolerability study in premature infants started in 2016 ☛ The active bact...
Read More

What we do

Infant Bacterial Therapeutics AB (publ) (“IBT”) is a pharmaceutical company with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. Using its extensive experience in live bacterial therape...
Read More